Sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study
June 6, 2025 | 62nd ERA Congress
Sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study
Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgA Nephropathy Treatment and Protective Immunity
June 5, 2025 | 62nd ERA Congress
Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgA Nephropathy Treatment and Protective Immunity
Sibeprenlimab in patients with IgA nephropathy: a Phase 2 trial
November 2, 2023 | American Society of Nephrology (ASN) Kidney Week
Sibeprenlimab in patients with IgA nephropathy: a Phase 2 trial
COVID Vaccine Responses During Sibeprenlimab Treatment of IgA Nephropathy (IgAN): A Preliminary Analysis
June 15, 2023 | 60th ERA Congress
COVID Vaccine Responses During Sibeprenlimab Treatment of IgA Nephropathy (IgAN): A Preliminary Analysis
Strategies For Development Of Interleukin-2 Therapy In Transplant Recipients: What Works And What Doesn’t
June 3, 2023 | American Transplant Congress
Strategies For Development Of Interleukin-2 Therapy In Transplant Recipients: What Works And What Doesn’t
A Novel IL-2 Mutein Induces Regulatory T Cell-Rich Microenvironment and Leads to Alloantigen-Specific Graft Acceptance
June 3, 2023 | American Transplant Congress
A Novel IL-2 Mutein Induces Regulatory T Cell-Rich Microenvironment and Leads to Alloantigen-Specific Graft Acceptance
Selective Regulatory T-Cell Expansion by A Novel IL-2 Mutein in Murine Transplant and Humanized NSG Models
June 3, 2023 | American Transplant Congress 2023
Selective Regulatory T-Cell Expansion by A Novel IL-2 Mutein in Murine Transplant and Humanized NSG Models
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients with Immunoglobulin A Nephropathy (IgAN)
November 5, 2022 | American Society of Nephrology (ASN) Kidney Week
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients with Immunoglobulin A Nephropathy (IgAN)
Interim Analysis (IA) of a Global Phase 2 Randomized Controlled Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in IgA Nephropathy
November 3, 2022 | American Society of Nephrology (ASN) Kidney Week
Interim Analysis (IA) of a Global Phase 2 Randomized Controlled Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in IgA Nephropathy
Role of APRIL in IgAN Pathophysiology
October 4, 2022 | Rare & Genetic Kidney Disease Drug Development Conference
Role of APRIL in IgAN Pathophysiology
- 1
- 2
- 3
- 4
- Next Page »